Nuzenio

Fda De Novo

Fda De Novo news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 6 latest news signals 6 publisher sources 100/100 entity strength

Latest news

CytoSorbents Q2 2026: Flat Revenue, Improved Cash Burn Ahead of DrugSorb-ATR FDA Decision - The Clinical Trial VanguardThe Clinical Trial Vanguard · Fri, 07 Aug 2026 06:44:00 GMTFDA Formally Classifies Active Noise Attenuation Systems for Infant Incubators as Class II Devices - The Hearing ReviewThe Hearing Review · Mon, 03 Aug 2026 15:16:45 GMTSmith+Nephew’s TESSA™ Spatial Surgery System granted De Novo classification by the FDA sparking a generational leap in Sports Medicine for personalized planning and procedural innovation - Ortho Spine NewsOrtho Spine News · Thu, 30 Jul 2026 18:25:39 GMTRecovryAI Completes Patient Phase of Pivotal Trial Evaluating Its Clinical AI in Advance of FDA De Novo Filing - Business WireBusiness Wire · Thu, 30 Jul 2026 16:28:00 GMTCaristo Diagnostics' CaRi-Heart® Coronary Inflammation Technology Authorized by U.S. FDA - PR NewswirePR Newswire · Wed, 29 Jul 2026 14:00:00 GMTFDA Grants De Novo Authorization for AI-Based Coronary Inflammation Quantification from CCTA Exams - diagnosticimaging.comdiagnosticimaging.com · Wed, 29 Jul 2026 07:00:00 GMT

Timeline

Fri, 07 Aug 2026 06:44:00 GMTCytoSorbents Q2 2026: Flat Revenue, Improved Cash Burn Ahead of DrugSorb-ATR FDA Decision - The Clinical Trial Vanguard
Mon, 03 Aug 2026 15:16:45 GMTFDA Formally Classifies Active Noise Attenuation Systems for Infant Incubators as Class II Devices - The Hearing Review
Thu, 30 Jul 2026 18:25:39 GMTSmith+Nephew’s TESSA™ Spatial Surgery System granted De Novo classification by the FDA sparking a generational leap in Sports Medicine for personalized planning and procedural innovation - Ortho Spine News
Thu, 30 Jul 2026 16:28:00 GMTRecovryAI Completes Patient Phase of Pivotal Trial Evaluating Its Clinical AI in Advance of FDA De Novo Filing - Business Wire
Wed, 29 Jul 2026 14:00:00 GMTCaristo Diagnostics' CaRi-Heart® Coronary Inflammation Technology Authorized by U.S. FDA - PR Newswire
Wed, 29 Jul 2026 07:00:00 GMTFDA Grants De Novo Authorization for AI-Based Coronary Inflammation Quantification from CCTA Exams - diagnosticimaging.com

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Fda De Novo.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

6 distinct publisher/source names are currently connected to this entity page.